ClinicaliQ Trial Snapshot
- Phase IIa Trial in Participants With Asthma to Evaluate Impact of Intranasal ETH47 on Development of Asthma-related Symptoms Following Rhinovirus Challenge — Recruiting • Phase II • Respiratory / COPD / Asthma • NCT07059767.
- Treatment being tested: Intranasal ETH47, a novel therapeutic agent administered via nasal spray, designed to prevent asthma symptom development triggered by rhinovirus infection in asthmatic patients.
- Patient eligibility: Participants with established asthma diagnoses who are willing to undergo controlled rhinovirus challenge testing; specific inclusion/exclusion criteria would determine baseline disease severity and concurrent medication use.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
A Phase IIa trial in participants with asthma to evaluate the impact of intranasal ETH47 on the development of asthma-related symptoms following rhinovirus challenge
Eligibility Snapshot
- : 1. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
- Participants aged ≥18 and ≤65 years at the time of obtaining informed consent. 3. Diagnosis of clinical asthma (>12% reversibility following short acting beta 2 agonist (SABA) treatment or PC20 methacholine challenge of 5 year pack history; current vapers may be included if willing to stop prior to Baseline.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.